WHO seeks clarification from Bharat Biotech on Covaxin, assembly to be held on November 3 for ‘remaining evaluation’

in an e-mail response Indian Express On the end result of Tuesday’s assembly on the grant of the EUL to Covaxin, the WHO mentioned that the TAG “expects to receive these clarifications from the manufacturer by the end of this week, and to reconvene for a final risk-benefit assessment.” Targets. On Wednesday, November 3″.

“The Technical Advisory Group for Emergency Use Listing (TAG-EUL) is an unbiased advisory group that gives suggestions to the WHO on whether or not a Covid-19 vaccine might be listed for emergency use underneath the EUL course of. The TAG met right this moment (26 October 2021) and determined that the worldwide use of the vaccine requires extra clarification from the producer to conduct a remaining EUL risk-benefit evaluation. Indian Express.

Last Monday, the WHO mentioned it was anticipating “an additional information” from Bharat Biotech on Covaxin, which WHO specialists are investigating for the grant of the EUL.

In a collection of tweets, the WHO mentioned it “cannot cut corners”, and the deadline for its emergency use checklist was depending on how shortly vaccine producers had been capable of present the required knowledge.

“We know that many people are waiting for the WHO recommendation for Covaxin to be added to the #COVID19 emergency use list, but we can’t cut corners – from recommending a product for emergency use First, we must evaluate it thoroughly to make sure it is safe. and effective,” WHO had mentioned.

The WHO approval is a vital step within the vaccine being accepted by international governments. The EUL is necessary to deal with the uncertainty about international journey by vaccinated Indians with this vaccine. The EUL can also be a prerequisite for vaccines provided by means of COVAX.